Back to Search Start Over

Clinical significance of mitochondrial DNA content in acute promyelocytic leukaemia.

Authors :
Pereira-Martins DA
Coelho-Silva JL
Weinhäuser I
Franca-Neto PL
Silveira DR
Ortiz C
Moreira-Aguiar A
Lima MM
Koury LC
de Melo RA
Glória AB
Fagundes EM
Lino BK
Pagnano K
Bittencourt R
Nunes E
Traina F
Figueiredo-Pontes L
Keating A
Tallman MS
Ribeiro RC
Dilon R
Ganser A
Sanz MA
Berliner N
Valk P
Löwenberg B
Ottone T
Noguera NI
Voso MT
Paoloni F
Fazi P
Ammatuna E
Huls G
Schuringa JJ
Rego EM
Lucena-Araujo AR
Source :
British journal of haematology [Br J Haematol] 2023 Jan; Vol. 200 (2), pp. 170-174. Date of Electronic Publication: 2022 Oct 20.
Publication Year :
2023

Abstract

Although a growing body of evidence demonstrates that altered mtDNA content (mtDNAc) has clinical implications in several types of solid tumours, its prognostic relevance in acute promyelocytic leukaemia (APL) patients remains largely unknown. Here, we show that patients with higher-than-normal mtDNAc had better outcomes regardless of tumour burden. These results were more evident in patients with low-risk of relapse. The multivariate Cox proportional hazard model demonstrated that high mtDNAc was independently associated with a decreased cumulative incidence of relapse. Altogether, our data highlights the possible role of mitochondrial metabolism in APL patients treated with ATRA.<br /> (© 2022 British Society for Haematology and John Wiley & Sons Ltd.)

Details

Language :
English
ISSN :
1365-2141
Volume :
200
Issue :
2
Database :
MEDLINE
Journal :
British journal of haematology
Publication Type :
Academic Journal
Accession number :
36263593
Full Text :
https://doi.org/10.1111/bjh.18510